Retatrutide in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Considerations

What Is Retatrutide and Why Does It Matter for Adolescents?

Retatrutide (LY3437943) is a single-molecule triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor simultaneously. Eli Lilly designed the compound to produce additive or synergistic metabolic effects beyond what dual agonists such as tirzepatide achieve. Adult Phase 2 data are striking, but no adolescent data exist.

The adult Phase 2 trial results

The key adult Phase 2 dose-finding trial (NCT04881760, N=338) published in the New England Journal of Medicine in 2023 showed mean body-weight reductions of 17.5% at 24 weeks and up to 24.2% at 48 weeks in the highest-dose cohort (12 mg weekly), compared with 2.1% in the placebo arm 1. These figures exceed what was seen with semaglutide 2.4 mg (14.9% at 68 weeks in STEP-1, N=1,961) 2 and with tirzepatide 15 mg (20.9% at 72 weeks in SURMOUNT-1, N=2,539) 3.

Why clinicians are asking about adolescent use

Adolescent obesity affects roughly 19.7% of U.S. Children and teens ages 2 to 19 according to CDC National Health and Nutrition Examination Survey data 4. When lifestyle intervention and approved pharmacotherapy fall short, some families and clinicians inquire about emerging agents. The large effect sizes from adult retatrutide trials have made it a topic of off-label discussion even though no pediatric data are available.

Current FDA Approval Status for Retatrutide

Retatrutide holds no FDA approval for any indication or age group as of July 2025. Eli Lilly has advanced the compound into Phase 3 adult trials for obesity and type 2 diabetes, but regulatory submissions have not been publicly announced for either adults or pediatric populations 5.

What "off-label" means legally

The FDA does not prohibit licensed physicians from prescribing approved drugs off-label. Retatrutide, however, is not approved at all. Dispensing an unapproved investigational compound outside a registered clinical trial raises distinct legal and ethical concerns beyond standard off-label prescribing. The FDA's guidance on expanded access (compassionate use) outlines a formal pathway, but that pathway requires an investigational new drug (IND) application and institutional oversight 6.

Compounded retatrutide: a separate concern

Some compounding pharmacies have begun offering retatrutide peptide preparations. The FDA has not authorized any compounded version of retatrutide, and compounded peptides fall outside the agency's drug approval standards for purity, potency, and sterility 7. This concern is amplified in adolescent patients, whose dose-response relationships are entirely unknown.

Adolescent Obesity Pharmacotherapy: The Approved Framework

Before considering any off-label agent, clinicians should exhaust guideline-concordant options. The American Academy of Pediatrics (AAP) 2023 clinical practice guideline recommends intensive health-behavior and lifestyle treatment as the foundation, with adjunctive pharmacotherapy offered when appropriate for patients ages 12 and older 8.

Approved agents in the 12 to 17 age range

Semaglutide 2.4 mg subcutaneous (Wegovy) received FDA approval for adolescents ages 12 and older with obesity (BMI at or above the 95th percentile) in December 2022, based on the STEP TEENS trial (N=201), which showed 16.1% mean body-weight reduction versus 0.6% with placebo at 68 weeks 9. Orlistat 120 mg has been approved for ages 12 and older since 1999, though its gastrointestinal tolerability profile limits adherence. Phentermine carries an off-label history in adolescents but lacks strong long-term pediatric data 10.

The Endocrine Society position

The 2023 Endocrine Society Clinical Practice Guideline on obesity pharmacotherapy states: "We recommend using pharmacotherapy as an adjunct to lifestyle intervention in patients with obesity where the benefits outweigh the risks, using agents with the strongest evidence base." 11. Retatrutide is not mentioned because no adolescent evidence existed at the time of publication.

Developmental Physiology: Why Adolescents Are Not Small Adults

Adolescent pharmacology differs from adult pharmacology in ways that make direct extrapolation of adult retatrutide data unreliable. Four developmental domains deserve specific attention.

1. Growth hormone and IGF-1 axes

The glucagon receptor component of retatrutide stimulates hepatic glucose production and affects growth hormone secretory dynamics. In adults, glucagon receptor agonism at therapeutic doses has not produced clinically significant growth hormone disruption. In adolescents, the growth hormone/IGF-1 axis is highly active, driving linear growth and lean mass accrual 12. No data clarify whether retatrutide's glucagon component could interfere with pubertal growth velocity or epiphyseal plate closure.

2. Bone mineral density accrual

Approximately 40% of peak bone mass is acquired during adolescence 13. GLP-1 receptor agonists have demonstrated mixed effects on bone turnover markers in adult trials. The long-term impact of combined GIP, GLP-1, and glucagon receptor agonism on adolescent bone mineral density accrual is unknown. This is not a theoretical concern: liraglutide 3.0 mg showed a modest but measurable reduction in bone mineral density Z-scores in a small pediatric cohort 14.

3. Reproductive hormones and puberty

Puberty depends on the coordinated activation of the hypothalamic-pituitary-gonadal axis. Significant caloric restriction, even when driven by an anorectic drug, can delay or disrupt puberty in adolescents with marginal energy balance. STEP TEENS with semaglutide showed no statistically significant difference in Tanner staging progression between groups at 68 weeks 9, but retatrutide produces substantially larger caloric deficits in adults, and its pubertal impact is unknown.

4. Hepatic and renal drug metabolism

Cytochrome P450 enzyme expression and renal glomerular filtration rates differ between adolescents and adults in ways that affect drug half-life and exposure. Retatrutide's pharmacokinetic profile was characterized in adults only (median age 46 years in the Phase 2 trial) 1. Pediatric pharmacokinetic studies are required by FDA's Pediatric Research Equity Act for new molecular entities, but that obligation applies at the time of adult approval, not before it 15.

Safety Signals From Adult Trials That Carry Heightened Weight in Adolescents

Adult Phase 2 retatrutide data identified several adverse-event patterns that warrant closer scrutiny when extrapolating to a younger population.

Nausea, vomiting, and caloric intake

In the adult Phase 2 trial, nausea occurred in 47% of participants in the 12 mg cohort and vomiting in 26%, predominantly during dose escalation 1. Adolescents in active growth require adequate protein and micronutrient intake to support lean mass and bone development. Persistent nausea severe enough to reduce dietary intake below growth requirements could produce nutritional deficits not seen in adults on the same regimen.

Heart rate elevation

Retatrutide increased mean resting heart rate by approximately 4 to 6 beats per minute in adult trials, a finding consistent with other GLP-1 receptor agonists 1. This effect has not been characterized in adolescents, whose baseline autonomic tone differs from adults. The American Heart Association notes that resting heart rate trajectories in adolescents are sensitive to autonomic dysregulation 16.

Gallbladder events

Rapid weight loss accelerates biliary cholesterol saturation and increases cholelithiasis risk. Adult GLP-1 receptor agonist trials, including SCALE Obesity with liraglutide (N=3,731), found gallbladder-related adverse events in 2.5% of treated patients versus 1.0% with placebo 17. Retatrutide's larger weight-loss magnitude could amplify this risk proportionally, and pediatric cholelithiasis, while uncommon, carries distinct procedural implications.

Comparing Retatrutide to Approved Adolescent Options

A direct head-to-head trial comparing retatrutide to semaglutide in adolescents does not exist. The following comparison draws from adult trial data and approved adolescent trial data and should not be used to justify clinical substitution.

| Agent | Population | Duration | Mean Weight Loss | Approval Status (Ages 12 to 17) | |---|---|---|---|---| | Semaglutide 2.4 mg | Adolescents (STEP TEENS, N=201) | 68 weeks | 16.1% | FDA-approved | | Tirzepatide 15 mg | Adults (SURMOUNT-1, N=2,539) | 72 weeks | 20.9% | Not approved adolescents | | Retatrutide 12 mg | Adults (Phase 2, N=338) | 48 weeks | 24.2% | Not approved any age |

Sources: 9, 3, 1.

The weight-loss data are not directly comparable across trials because trial design, endpoints, and populations differ. The table illustrates the evidentiary gap: semaglutide has adolescent-specific randomized controlled trial data; retatrutide does not.

What a Clinician Should Do When a Family Asks About Retatrutide

Families sometimes present to consultations having researched retatrutide independently. A clear, structured response prevents both dismissiveness and inappropriate prescribing.

Step 1: Clarify the evidence gap

Explain that retatrutide's impressive adult numbers come from a 48-week Phase 2 trial. No data in any patient under 18 exist. The 24.2% adult weight-loss figure cannot be assumed to replicate in a 14-year-old whose physiology, metabolism, and organ development differ substantially.

Step 2: Review approved options systematically

Confirm whether the adolescent has completed an intensive health-behavior and lifestyle intervention of at least 26 contact hours, per AAP guideline thresholds 8. If semaglutide 2.4 mg has not been tried, it is the evidence-based next step, not an investigational compound.

Step 3: Address comorbidity severity

Some adolescents present with obesity-related comorbidities (type 2 diabetes, severe obstructive sleep apnea, nonalcoholic fatty liver disease) that may justify more aggressive intervention. Even in those cases, the appropriate escalation pathway runs through metabolic and bariatric surgery centers with adolescent programs, not unapproved compounds. The AAP guideline explicitly endorses referral for metabolic and bariatric surgery in adolescents ages 13 and older with severe obesity 8.

Step 4: Document the conversation

If a family declines approved options and continues to request retatrutide, document the informed-refusal discussion, including the absence of pediatric safety data, the unapproved status, and the alternative options offered. Institutions offering any investigational compound to adolescents outside a registered clinical trial should involve their institutional review board.

Ongoing Research and What to Watch For

Eli Lilly is currently running Phase 3 adult trials for retatrutide in obesity (NCT05882045) and type 2 diabetes 18. Pediatric pharmacokinetic and safety studies are legally required under PREA once adult approval occurs, but those studies typically begin after adult approval, not before. Realistically, adolescent-specific retatrutide data are at minimum four to five years away, assuming adult approval proceeds on schedule.

Clinicians should monitor:

• ClinicalTrials.gov for any newly registered adolescent retatrutide arms
• FDA new drug application (NDA) filings, which would trigger PREA pediatric study requirements 15
• Peer-reviewed pharmacokinetic modeling studies that may extrapolate dosing to adolescents, with caution
• The Obesity Society and AAP guideline update cycles for formal positioning statements on triple agonists

Monitoring Parameters If Off-Label Use Proceeds in a Research Context

This section describes parameters relevant only to registered clinical research. These are not instructions for community prescribing.

Within a formal IND or institutional protocol, adolescent participants receiving retatrutide would require monitoring beyond standard adult protocols. Relevant additions include: serial height and weight with growth velocity calculations every 12 weeks; dual-energy X-ray absorptiometry (DXA) scans at baseline, 26 weeks, and 52 weeks for bone mineral density Z-scores; Tanner staging at each visit; fasting insulin-like growth factor-1 (IGF-1) levels; continuous glucose monitoring in any participant with prediabetes; and gallbladder ultrasound at baseline and 24 weeks given the high expected weight-loss rate 19.

The Pediatric Endocrine Society notes that any clinical trial involving weight-loss pharmacotherapy in adolescents should include a registered dietitian conducting dietary assessments to confirm micronutrient and protein adequacy throughout the trial period 20.